SAGITTA contains imatinib mesylate, a second generation tyrosine kinase inhibitor, as hard capsules, is available in the following dosage forms: - 100mg capsules, packs of 60 - 400mg capsules, packs of 30

SAGITTA is indicated for the treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblasti

Zahrt Aleklil is a leading company in the field of medical services, with a long history of investments in the field of sale, distribution, and provisions of all requirements of the highest standards.


Hay Al Andalus, near the 7th of October Market, Tripoli, Libya